Cargando…

Endothelial Progenitor Cells Are Related to Glycemic Control in Children With Type 1 Diabetes Over Time

OBJECTIVE: The risk of cardiovascular death before the age of 40 is 20-fold higher in patients with type 1 diabetes mellitus (T1DM). Endothelial progenitor cells (EPCs) predict cardiovascular morbidity and mortality in patients without diabetes. We hypothesized that EPCs are modified in children wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hörtenhuber, Thomas, Rami-Mehar, Birgit, Satler, Miriam, Nagl, Katrin, Höbaus, Clemens, Höllerl, Florian, Koppensteiner, Renate, Schernthaner, Guntram, Schober, Edith, Schernthaner, Gerit-Holger
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2013
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3661838/ https://www.ncbi.nlm.nih.gov/pubmed/23340890 http://dx.doi.org/10.2337/dc12-1206

Ejemplares similares

Angiogenin—A Proposed Biomarker for Cardiovascular Disease—Is Not Associated With Long-Term Survival in Patients With Peripheral Artery Disease
por: Höbaus, Clemens, et al.
Publicado: (2021)

Peripheral arterial disease and type 2 diabetes: Older patients still exhibit a survival benefit from glucose control
por: Höbaus, Clemens, et al.
Publicado: (2020)

Vascular peroxidase 1 is independently associated with worse kidney function in patients with peripheral artery disease
por: Costas, Lavinia, et al.
Publicado: (2020)

Thrombospondin-4 increases with the severity of peripheral arterial disease and is associated with diabetes
por: Zierfuss, Bernhard, et al.
Publicado: (2019)

NT-proBNP as a surrogate for unknown heart failure and its predictive power for peripheral artery disease outcome and phenotype
por: Zierfuss, Bernhard, et al.
Publicado: (2023)

Soluble urokinase-type plasminogen activator receptor predicts peripheral artery disease severity and outcomes
por: Höbaus, Clemens, et al.
Publicado: (2021)

Fetuin-A Levels Are Increased in Patients With Type 2 Diabetes and Peripheral Arterial Disease
por: Lorant, David Peter, et al.
Publicado: (2011)

YKL-40 and its complex association with metabolic syndrome, obesity, and cardiovascular disease
por: Schernthaner, Gerit-Holger, et al.
Publicado: (2016)

Do We Still Need Pioglitazone for the Treatment of Type 2 Diabetes? A risk-benefit critique in 2013
por: Schernthaner, Guntram, et al.
Publicado: (2013)

The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system
por: Schernthaner, Guntram, et al.
Publicado: (2014)

Renal Function but Not Asymmetric Dimethylarginine Is Independently Associated with Retinopathy in Type 2 Diabetes
por: Krzyzanowska, Katarzyna, et al.
Publicado: (2011)

Cure of Type 2 Diabetes by Metabolic Surgery? A Critical Analysis of the Evidence in 2010
por: Schernthaner, Guntram, et al.
Publicado: (2011)

Decrease of dipeptidyl peptidase 4 activity is associated with weight loss after bariatric surgery
por: Herz, Carsten T., et al.
Publicado: (2021)

Individualisierung der antihypertensiven Therapie bei Patient:innen mit Diabetes mellitus. Leitlinie der Österreichischen Diabetes Gesellschaft (Update 2023)
por: Saely, Christoph H., et al.
Publicado: (2023)

Diabetes in the older patient: heterogeneity requires individualisation of therapeutic strategies
por: Schernthaner, Guntram, et al.
Publicado: (2018)

Can glucose-lowering drugs affect the prognosis of COVID-19 in patients with type 2 diabetes?
por: Schernthaner, Guntram
Publicado: (2021)

Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19 (Diabetes Metab J 2021;45:251-9)
por: Schernthaner, Guntram
Publicado: (2021)

To the editor regarding article “Coadministration of DPP-4 inhibitor and insulin therapy does not further reduce the risk of cardiovascular events compared with DPP-4 inhibitor therapy in diabetic foot patients: a nationwide population-based study”
por: Mayer, Florian J., et al.
Publicado: (2018)

Hypoglycemia and Cardiovascular Risks
por: Frier, Brian M., et al.
Publicado: (2011)

Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea: A 52-week randomized trial
por: Schernthaner, Guntram, et al.
Publicado: (2013)

The management of type 2 diabetes before, during and after Covid-19 infection: what is the evidence?
por: Czupryniak, Leszek, et al.
Publicado: (2021)

Glucose-lowering therapy in type 2 diabetes: New hope after the EMPA-REG outcome trial
por: Schernthaner, G., et al.
Publicado: (2016)

Variability in and predictors of glycaemic responses after 24 weeks of treatment with exenatide twice daily and exenatide once weekly
por: Shaw, Jonathan E., et al.
Publicado: (2017)

Relevance of positive cardiovascular outcome trial results in clinical practice: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D)
por: Schernthaner, Guntram, et al.
Publicado: (2017)

Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes
por: Schernthaner, Guntram, et al.
Publicado: (2017)

The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy
por: Fouqueray, Pascale, et al.
Publicado: (2013)

Slope of change in HbA(1c) from baseline with empagliflozin compared with sitagliptin or glimepiride in patients with type 2 diabetes
por: DeFronzo, Ralph A., et al.
Publicado: (2018)

Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study
por: Simó, Rafael, et al.
Publicado: (2015)

Nearly Fatal Torsade de Pointes with Sotalol
por: Strohmer, Bernhard, et al.
Publicado: (2003)

Coexistence of Atrioventricular Nodal Reentrant Tachycardia with Other Forms of Arrhythmias
por: Schernthaner, Christiana, et al.
Publicado: (2014)

The importance of socio-economic determinants of health in the care of patients with peripheral artery disease: A narrative review from VAS
por: Kolossváry, Endre, et al.
Publicado: (2023)

Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 2013;36:2508–2515
por: Schernthaner, G, et al.
Publicado: (2013)

Comparison of endothelial progenitor cell function in type 2 diabetes with good and poor glycemic control
por: Churdchomjan, Worachat, et al.
Publicado: (2010)

Physiotherapy as a Rare Cause of Twiddler’s Syndrome in a Patient With an Implanted Cardioverter Defibrillator
por: Schernthaner, Christiana, et al.
Publicado: (2013)

Injektionstherapie (GLP1-Rezeptor Agonisten und Insulin) bei Typ 2 Diabetes mellitus (Update 2023)
por: Lechleitner, Monika, et al.
Publicado: (2023)

Response to Comment on Home et al. Insulin Therapy in People With Type 2 Diabetes: Opportunities and Challenges? Diabetes Care 2014;37:1499–1508
por: Home, Philip, et al.
Publicado: (2014)

Insulin Therapy in People With Type 2 Diabetes: Opportunities and Challenges?
por: Home, Philip, et al.
Publicado: (2014)

Epigenetic Changes in Endothelial Progenitors as a Possible Cellular Basis for Glycemic Memory in Diabetic Vascular Complications
por: Rajasekar, Poojitha, et al.
Publicado: (2015)

Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site
por: Hadzijusufovic, Emir, et al.
Publicado: (2017)

Microglia prevent peripheral immune cell invasion and promote an anti-inflammatory environment in the brain of APP-PS1 transgenic mice
por: Unger, M. S., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_qenuee0isbpm6sgmvajq1mo123